BACKGROUND AND OBJECTIVES:Endothelin A receptor antagonists (ERAs) decrease residual albuminuria in patients with diabetic kidney disease; however, their clinical utility may be limited by fluid retention. Consequently, the primary objective of this study was to identify predictors for ERA-induced fluid retention among patients with type 2 diabetes and CKD. A secondary objective was to determine if the degree of fluid retention necessarily correlated with the magnitude of albuminuria reduction in those patients receiving ERAs. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A post hoc analysis was conducted of the phase IIb atrasentan trials assessing albuminuria reduction in 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 ml/min per 1.73 m(2) who were randomly assigned to receive placebo (n=50) or atrasentan 0.75 mg/d (n=78) or 1.25 mg/d (n=83) for 12 weeks. Changes in body weight and hemoglobin (Hb) after 2 weeks of treatment were used as surrogate markers of fluid retention. RESULTS: Baseline predictors of weight gain after 2 weeks of atrasentan treatment were higher atrasentan dose, lower eGFR, higher glycated hemoglobin, higher systolic BP, and lower homeostatic metabolic assessment product. Higher atrasentan dose and lower eGFR also predicted decreases in Hb. There were no changes in B-type natriuretic peptide. There was no correlation between reduction in albuminuria after 2 weeks of atrasentan treatment and changes in body weight or Hb. CONCLUSIONS: In the Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan/JAPAN trials, atrasentan-associated fluid retention was more likely in patients with diabetes and nephropathy who had lower eGFR or received a higher dose of atrasentan. Finding that albuminuria reduction was not associated with changes in body weight and Hb suggests that the albuminuria-reducing efficacy of atrasentan is not impaired by fluid retention.
RCT Entities:
BACKGROUND AND OBJECTIVES: Endothelin A receptor antagonists (ERAs) decrease residual albuminuria in patients with diabetic kidney disease; however, their clinical utility may be limited by fluid retention. Consequently, the primary objective of this study was to identify predictors for ERA-induced fluid retention among patients with type 2 diabetes and CKD. A secondary objective was to determine if the degree of fluid retention necessarily correlated with the magnitude of albuminuria reduction in those patients receiving ERAs. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A post hoc analysis was conducted of the phase IIb atrasentan trials assessing albuminuria reduction in 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 ml/min per 1.73 m(2) who were randomly assigned to receive placebo (n=50) or atrasentan 0.75 mg/d (n=78) or 1.25 mg/d (n=83) for 12 weeks. Changes in body weight and hemoglobin (Hb) after 2 weeks of treatment were used as surrogate markers of fluid retention. RESULTS: Baseline predictors of weight gain after 2 weeks of atrasentan treatment were higher atrasentan dose, lower eGFR, higher glycated hemoglobin, higher systolic BP, and lower homeostatic metabolic assessment product. Higher atrasentan dose and lower eGFR also predicted decreases in Hb. There were no changes in B-type natriuretic peptide. There was no correlation between reduction in albuminuria after 2 weeks of atrasentan treatment and changes in body weight or Hb. CONCLUSIONS: In the Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan/JAPAN trials, atrasentan-associated fluid retention was more likely in patients with diabetes and nephropathy who had lower eGFR or received a higher dose of atrasentan. Finding that albuminuria reduction was not associated with changes in body weight and Hb suggests that the albuminuria-reducing efficacy of atrasentan is not impaired by fluid retention.
Authors: Donald E Kohan; Yili Pritchett; Mark Molitch; Shihua Wen; Tushar Garimella; Paul Audhya; Dennis L Andress Journal: J Am Soc Nephrol Date: 2011-03-03 Impact factor: 10.121
Authors: René R Wenzel; Thomas Littke; Susan Kuranoff; Christiane Jürgens; Heike Bruck; Eberhard Ritz; Thomas Philipp; Anna Mitchell Journal: J Am Soc Nephrol Date: 2009-01-14 Impact factor: 10.121
Authors: Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: Dick de Zeeuw; Blai Coll; Dennis Andress; John J Brennan; Hui Tang; Mark Houser; Ricardo Correa-Rotter; Donald Kohan; Hiddo J Lambers Heerspink; Hirofumi Makino; Vlado Perkovic; Yili Pritchett; Giuseppe Remuzzi; Sheldon W Tobe; Robert Toto; Giancarlo Viberti; Hans-Henrik Parving Journal: J Am Soc Nephrol Date: 2014-04-10 Impact factor: 10.121
Authors: Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti Journal: J Am Soc Nephrol Date: 2010-02-18 Impact factor: 10.121
Authors: Deborah Stuart; Sara Rees; Stephanie K Woodward; Robert Koesters; Kevin A Strait; Donald E Kohan Journal: BMC Nephrol Date: 2012-12-05 Impact factor: 2.388
Authors: Simke W Waijer; Ron T Gansevoort; George L Bakris; Ricardo Correa-Rotter; Fan-Fan Hou; Donald E Kohan; Dalane W Kitzman; Hirofumi Makino; John J V McMurray; Vlado Perkovic; Sheldon Tobe; Hans-Henrik Parving; Dick de Zeeuw; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2021-12-01 Impact factor: 8.237
Authors: Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz Journal: Toxins (Basel) Date: 2018-06-12 Impact factor: 4.546
Authors: Sergei I Petrykiv; Gozewijn Dirk Laverman; Frederik Persson; Liffert Vogt; Peter Rossing; Martin H de Borst; Ronald T Gansevoort; Dick de Zeeuw; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2017-10-11 Impact factor: 8.237
Authors: Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire Journal: Pharmacol Rev Date: 2016-04 Impact factor: 25.468
Authors: Osvaldo Rivera-Gonzalez; Natalie A Wilson; Laura E Coats; Erin B Taylor; Joshua S Speed Journal: Clin Sci (Lond) Date: 2021-07-30 Impact factor: 6.876